Zonampanel

Zonampanel

Systematic (IUPAC) name
[7-(1H-Imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydro-1(2H)-quinoxalinyl]acetic acid
Identifiers
CAS Number	210245-80-0
ATC code	None
PubChem	CID 148200
ChemSpider	130649
Chemical data
Formula	C13H9N5O6
Molar mass	331.241 g/mol
SMILES c1cn(cn1)c2cc3c(cc2[N+](=O)[O-])[nH]c(=O)c(=O)n3CC(=O)O
InChI InChI=1S/C13H9N5O6/c19-11(20)5-17-8-4-9(16-2-1-14-6-16)10(18(23)24)3-7(8)15-12(21)13(17)22/h1-4,6H,5H2,(H,15,21)(H,19,20) Key:SPXYHZRWPRQLNS-UHFFFAOYSA-N

Zonampanel (INN, code name YM872) is a quinoxalinedione derivative drug and competitive antagonist of the AMPA receptor which was being investigated by Yamanouchi/Astellas Pharma as a neuroprotective drug for the treatment of ischemic stroke but never completed clinical trials.^[1][2][3][4] In clinical trials, zonampanel produced severe side effects including hallucinations, agitation, and catatonia in patients, resulting in early termination of the trials.^[5]

See also

• Fanapanel
• Irampanel

References

1. Kewal K. Jain (14 February 2011). The Handbook of Neuroprotection. Springer Science & Business Media. pp. 154–. ISBN 978-1-61779-049-2.
2. Arunabha Ray, Kavita Gulati (1 January 2007). Current Trends in Pharmacology. I. K. International Pvt Ltd. pp. 321–. ISBN 978-81-88237-77-7.
3. Stephen Waxman (27 May 2005). Multiple Sclerosis As A Neuronal Disease. Academic Press. pp. 245–. ISBN 978-0-08-048941-4.
4. Santokh Gill; Olga Pulido (31 January 2007). Glutamate Receptors in Peripheral Tissue: Excitatory Transmission Outside the CNS. Springer Science & Business Media. pp. 37–. ISBN 978-0-306-48644-9.
5. Akhlaq A. Farooqui (2 September 2010). Neurochemical Aspects of Neurotraumatic and Neurodegenerative Diseases. Springer Science & Business Media. pp. 73–. ISBN 978-1-4419-6652-0.